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A B S T R A C T
Purpose: Antiepileptic drugs have been reported to reduce the levels of serum immunoglobulins and
affect the production and levels of certain cytokines. We investigated the effects of valproic acid (VPA)
and topiramate (TPM) on the blood levels of interleukin (IL)-1a, IL-1b, IL-6, IL-10, and TNF-a in children
with idiopathic generalized and partial epilepsy.
Methods: Forty prepubertal children aged 6–12 (mean 8.3  1.7) years, 19/40 (47.5%) female and 21/40
(52.5%) male, with idiopathic generalized or partial epilepsy diagnosed in the child neurology outpatient
clinic were included. The patients were divided into two treatment groups: 20 were treated with VPA and 20
with TPM. The plasma levels of IL-1a, IL-1b, IL-6, IL-10, TNF-a were measured using ELISA method before the
initiation of treatment and at the 6th and 12th months of the treatment. The Chi-square test was used to
compare qualitative data. To compare the periods, recurrence measurements were done using variance
analysis and Freidman 2-sided variance analysis. p < 0.05 was considered as statistically signiﬁcant.
Results: In the VPA group, the levels of IL-1a signiﬁcantly increased at 12 months while the levels of IL-
10 decreased at 6 months of treatment compared to values before treatment (p < 0.05). There was no
signiﬁcant difference in levels of IL-1b, IL-6, TNF-a (p > 0.05). In the TPM group, lower levels of IL-10
were observed at 6th and 12th months compared to the onset of treatment (p < 0.05).
Conclusion: The results of this study demonstrated that VPA and TPM might lead to changes in the levels
of cytokines in epileptic patients. The next step would be to investigate the relation of these ﬁndings to
the outcome of epilepsy and response to treatment.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a disease affecting 0.5–1% of the child population.1
Efﬁcient anti-epileptic treatment is available for most cases,
although hematological, biochemical and gastrointestinal side
effects are not rare in long-term use. Anti-epileptic drugs also act
on the immune system.2 They reduce the serum levels of
immunoglobulins3–5 and affect the production of cytokines.1
Cytokines are chemical conduction molecules which mediate
the development and regulation of the inﬂammatory and immune* Corresponding author. Current address: Turgut Ozal University, Faculty of
Medicine, Department of Child Neurology, Alparslan Turkes Caddesi, No. 57 Emek,
Ankara, Turkey. Tel.: +90 312 203 5258; fax: +90 533 6548654.
E-mail address: mjgsonmez@yahoo.com (F.M. Sonmez).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.03.014responses.1–5 The bidirectional correlation between the central
nervous system (CNS) and immune system is mostly mediated by
cytokines.6,7 Inﬂammation may facilitate if not cause the
development of epilepsy, epileptic seizures can trigger an
inﬂammatory response.8 Experimental and clinical ﬁndings
support a crucial role of inﬂammatory processes in epilepsy.9
Interleukin-1 receptor antagonist (IL-1Ra) has neuroprotective
effects in experimental status epilepticus10, and IL-6 has neuro-
protective and anticonvulsive effects after kainic acid-induced
status epilepticus.11 Increased levels of IL-6 and IL-1Ra were
reported after single generalized or prolonged seizures.12 In-
creased post-ictal serum levels of IL-6, IL-1b, IL-2, IL-4 and
interferon (IFN)-g were described by Sinha et al.13
Recent studies reported that certain anti-epileptic drugs (AEDs)
have important effects on the production of inﬂammatory
cytokines.5,14,15 The action of AEDs might even affect their impactvier Ltd. All rights reserved.
Table 1
The distribution of the patients in Group I and Group II by gender and type of seizure.
Type of seizure Group 1 (n = 20) Group 2 (n = 20) Total (n = 40)
Female Male Female Male
(n = 10, %50) (n = 10, %50) (n = 9, %45) (n = 11, %55) (n = 40, %100)
Generalized 3 (%30) 2 (%20) 1 (%11, 11) 0 (%0) n = 6 (%15)
Partial 7 (%70) 8 (%80) 8 (%88, 89) 11 (%100) n = 34 (%85)
Table 2
Types of seizures and EEG results of the patients.
Type of seizure n % EEG ﬁndings n %
Simple partial 12 30 Epileptiform activity
Complex partial 22 55 Focal 30 75
JTK 3 7.5 Generalized 8 20
Tonic 1 2.5
Clonic 1 2.5 Paroxysmal anomaly 2 5
Absence 1 2.5
Total 40 100 Total 40 100
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not been fully understood. In particular, reports on the effect of
AEDs on interleukin (IL) levels have been scarce and conﬂict-
ing.2,14,15,17 We therefore aimed to investigate the effects of
valproic acid (VPA), an old-generation AED, and topiramate (TPM),
a newer AED on the blood levels of IL-1a, IL-1b, IL-6, IL-10 and
tumor necrosis factor (TNF)-a.
2. Methods
We enrolled a total of 40 prepubertal patients, 19 (47.5%)
females and 21 (52.5%) males, whose ages ranged between 6 and
12 years (mean 8.3  1.7 years). These patients presented with
seizures to the outpatient clinic of pediatric neurology between 2009
and 2010 and were diagnosed with idiopathic generalized or partial
epilepsy, based on history, neurologic examination, electroencepha-
lography (EEG), and magnetic resonance imaging (MRI).
Exclusion criteria included mental retardation, abnormal
ﬁndings on neurologic examination or MRI, previous history of
status epilepticus, previous history of AED use, immunosuppres-
sive therapy, autoimmune disease, thyroid, liver or kidney disease,
immune deﬁciency, or the presence of an infection at the time of
diagnosis.
The patients were treated with VPA or TPM according to clinical
or EEG ﬁndings: as both drugs are effective in generalized and
partial seizures, the treatment decision was made considering the
child’s age, sex, and body weight. Group I consisted of 20 patients
treated with VPA 20 mg/kg/day and Group II of 20 patients treated
with TPM 3 mg/kg/day. TPM was initiated at the dose of 0.5 mg/kg/
day, and was increased by 1 mg/kg/day once a week up to 3 mg/kg/
day.
Ethical approval was obtained from the Ethical Board of
Karadeniz Technical University, Faculty of Medicine (date:
23.03.2009, number: 2009/28).
All measurements were made in venous blood samples
obtained between 7:30 and 8:30 a.m. following a fasting period
of at least 10–12 h initially and at least 10–12 h after the last AED
intake at the 6th and 12th months. Three samples were drawn
from each patient: at baseline, and at the 6th and 12th months of
treatment. Care was taken to obtain the samples during an
infection-free and seizure-free period of at least one week. Samples
were centrifuged at 3000 rpm for 15 min and sera were stored at
80 8C until the study. On the study day, all sera were thawed at
the same time and tested on the same day for IL-1a, IL-1b, IL-6, IL-
10, and TNF-a (Assay-Pro, USA) levels using the enzyme-linked
immunosorbent assay (ELISA) method. Baseline, and 6th and 12th
month measurements were compared.
The AED levels were not measured at the various time points
when blood sampling was performed (6th and 12th months).
2.1. Statistical analysis
Statistical analyses were performed using The Statistical
Package for The Social Sciences software (SPSS 13.0.1 serial
number: 9069728). Descriptive statistics were used.The Chi-square test was used to compare qualitative data. In
each group, conformity of the measured values to the normal
distribution was analyzed by using Kolmogorov–Smirnov test.
Variation during the period for the data showing skewed
distribution was analyzed using Friedman test and p < 0.005
was determined as statistically signiﬁcant. Post hoc by Wilcoxon
test using Bonferroni correction to adjust for multiple comparisons
in each group.
3. Results
Thirty-four subjects (85%) were diagnosed with idiopathic
partial epilepsy and 6 (15%) with idiopathic generalized epilepsy.
Group I included 20 patients, 10 males (50%) and 10 females (50%),
and Group II 20 patients, 9 (45%) females and 11 (55%) males
(Table 1). There was no signiﬁcant difference in the age and gender
distribution of the two treatment groups. The most common
seizure types were complex partial (55%) and simple partial (30%)
(Table 2). The most common EEG ﬁnding was focal epileptiform
activity (75%) (Table 2). The rate of seizure control was similar
between the two groups.
3.1. Laboratory ﬁndings
In Group I, treated with VPA, the levels of IL-1a were increased
at the 6th and 12th months, with the 12-month level being
signiﬁcantly increased compared to baseline (p < 0.05) (Table 3).
No signiﬁcant change was observed in the levels of IL-1b, IL-6, and
TNF-a (p > 0.05) (Table 3).
The levels of IL-10 showed a signiﬁcant decrease compared to
baseline at 6th month of VPA treatment (p < 0.05) (Table 3).
In Group II treated with TPM, the levels of IL-10 diminished
signiﬁcantly at the 6th and 12th months compared to pre-
treatment levels (Table 4). Alterations in the levels of other
cytokines were not signiﬁcant (Table 4).
4. Discussion
Studies in epileptic patients and also in animal models revealed
changes in the expression of cytokines and immune cells.12,18,19
Moreover, the anticonvulsive activity of anti-inﬂammatory drugs,
namely steroids and ACTH, even on seizures which that are
refractory to other AEDs, suggest that inﬂammation may play a role
in the pathogenesis of the epilepsy.9,20,21
Table 3
Levels of IL-a, IL-1b, IL-6, IL-10, TNF-a at baseline, 6th month and at 12th month of treatment with valproic acid.
Cytokines Baseline 6th month 12th month p*
IL-1a (pg/mL) 195.50  105.65a 208.50  117.66 231.50  110.41b 0.017
IL-1b (pg/mL) 18,222.74  29,265.65 11,075.00  19,041.65 11,289.13  18,773.35 0.705
IL-6 (ng/mL) 18.23  19.85 13.26  15.86 13.65  14.33 0.086
IL-10 (ng/mL) 2562.55  4065.35d 1470.32  2599.27e 1609.07  2646.96 0.006
TNF-a (ng/mL) 44.56  50.72 34.58  8.01 44.66  39.10 0.861
a–b and d–e: Signiﬁcant difference at the level of p < 0.05.
* Freidman test.
Table 4
Levels of IL-a, IL-1b, IL-6, IL-10, TNF-a at baseline, at 6th month and at 12th month of the treatment with topiramate.
Cytokines Baseline 6th month 12th month p*
IL-1a (pg/mL) 180.00  47.46 63.00  52.92 183.50  82.09 0.163
IL-1b (pg/mL) 3822.54  5489.41 4364.95  5494.85 3119.46  3672.47 0.705
IL-6 (ng/mL) 10.81  24.31 9.73  17.45 8.58  13.13 0.705
IL-10 (ng/mL) 474.82  544.44a 415.50  647.63b 310.97  366.36c 0.003
TNF-a (ng/mL) 40.83  47.46 38.92  36.25 35.48  20.09 0.951
a–b: Signiﬁcant difference at the level of p < 0.05 Wilcoxon test using Bonferroni correction.
a–c: Signiﬁcant difference at the level of p < 0.05 Wilcoxon test using Bonferroni correction.
* Freidman test.
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recognized a long time.16 VPA and phenobarbital diminish
humoral and cytotoxic T lymphocyte response in mice.22,23
Suppressor T cells were markedly decreased in the serum of
patients treated with phenytoin.24 Prenatal exposure to diazepam
decreased the production of T lymphocytes.25 However, these
studies mostly involve ﬁrst-generation AEDs. Furthermore, their
results are frequently inconsistent and occasionally conﬂicting.16 A
major source of discrepancy may be in the difﬁculty of
distinguishing the effect of the drugs from the effect of the
seizures.26 Moreover, personal and genetic predisposition, con-
comitant use of multiple drugs, and drug interactions are other
possible additional factors.16
There are few data examining the effect of the new AEDs on the
immune system. TPM reversed the decrease of in T-lymphocyte
proliferation activity induced by the seizure in rats.27 The purpose
of our study was to investigate the effects of one old (VPA) and one
new (TPM) drug on the levels of IL-1a, IL1b, IL-6, IL-10 and TNF-a.
The level of IL-1 is very low in the CNS.19 It has both neurotoxic
and neuroprotective effects.8 Stimuli with a convulsant effect
increase the production of IL-1b in microglia-like cells in the
hypocampus.1 Verrotti et al.14 examined the levels of IL-1a, IL-1b,
IL-2, and IL-6 (from peripheral blood mononuclear cells) in 40
patients aged 8.9–16.2 years, treated with VPA and carbamazepine
(CBZ) monotherapy and, reported that the group treated with VPA
showed statistically signiﬁcant increase in the levels of IL-1a, IL-
1b, and IL-6 and no change in the levels of IL-2, whereas the CBZ
group showed an increase in all parameters. In this study, the blood
levels of cytokines in 48 healthy children were reported for IL1a,
IL-1b, IL-6 as 13.8  1.9 ng/ml, 1.02  0.32 ng/ml and
4.03  1.26 ng/ml, respectively. They did not ﬁnd a signiﬁcant
differences between the control group and epileptic patients. In
our study, the group treated with VPA showed an increase in IL-1a
level at the 6th and especially the 12th month of treatment. In our
study, although not statistically signiﬁcant, a VPA-related decrease
observed in the level in IL-1b may be signiﬁcant in terms of the
neuroprotective efﬁcacy of VPA.
IL-6 is a pleiotropic cytokine.1 Although VPA inhibits the
production of TNF-a and IL-6 in vitro, epileptic patients treated
with this drug show increased concentrations of IL-1, IL-6 and IL-
5.14 Verrotti et al.14 showed increased levels of IL-6, IL-1aand IL-1b with VPA at the 12th month compared to pre-
treatment. Shiah et al.15 gave 1000 mg per day of VPA to 10
healthy male volunteers aged 29.4  10.5 years for 7 days: levels
of IL-6 were signiﬁcantly increased. Kim et al.28 randomized the
patients with bipolar disorder to three groups, and treated 15
patients with VPA, 8 patients with lithium and 8 patients with
VPA + lithium. At the beginning of the therapy, they measured the
levels of IL-6, IL-4, IL-2, TNF-a, and IFN-g.
They found signiﬁcantly higher levels of IL-6 and TNF-a and
signiﬁcantly lower levels of IL-4 in patients compared to the
control group. All three groups showed a signiﬁcant decrease in
IL-6 levels at the end of the 6-week therapy compared to
baseline.
However, certain other studies have suggested that VPA
reduced or did not change the level of IL-6.5,29,30 In 10 adult
patients diagnosed with mania, Maes et al.29 reported that the
plasma levels of IL-6, soluble IL-6 receptor (sIL-6R), soluble IL-2
receptor (sIL-2R) and Transferrin receptor (TfR) remained un-
changed following short-term VPA monotherapy, as while De Ponti
et al.5 reported unchanged IL-6 levels under the same conditions.
In an experimental study, Ichiyama et al.30 suggested that VPA
acted by inhibiting the production of TNF-a and IL-6 resulting from
lipopolysaccharide pathway via human monocytic leukemic cells,
leading to the activation of NF-kB. Our results showing a non-
signiﬁcant decrease in the levels of IL-6 at the 6th and 12th months
in patients treated with VPA do not conﬂict with the results of Kim
and Ichiyama.
TNF-a is a proinﬂammatory cytokine that shows a neurotropic
and neurotoxic effect in the CNS.18 Animal studies have
demonstrated that the levels of TNF-a mRNA were increased
after the seizure and returned to basal levels at the end of 3
weeks.31 Ichiyama et al.30 showed in in vitro models that VPA
inhibited the production of TNF-a and IL-6. In the study performed
by Kim et al.28 the levels of TNF-a showed a statistically
insigniﬁcant decrease following 6-week treatment with VPA,
lithium and VPA + lithium.
In our study, TNF-a levels decreased at the 6th month of VPA
treatment and returned to baseline levels at 12th month; however,
changes were not signiﬁcant. The results obtained were inade-
quate to suggest that VPA may show a neuroprotective effect by
decreasing the level of TNF-a.
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cytokine synthesis inhibitor factor (CSIF).32 IL-10 limits inﬂamma-
tion in the brain. In addition, it accounts for the inhibition of the
synthesis of proinﬂammatory agents, such as interferon-g (IFN-g),
IL-2, IL-3, TNF-a, and granulocyte macrophage colony-stimulating
factor (GM-CSF).33 In our study, the levels of IL-10 showed a
decrease at the 6th and 12th months of treatment compared to the
pre-treatment period in both the VPA and TPM groups. However,
only the decrease observed at the 6th month compared to baseline
was statistically signiﬁcant in the VPA group. In the group treated
with TPM, the levels of IL-10 decreased signiﬁcantly at the 6th and
12th months.
To our knowledge, no other study has investigated the effect of
VPA and TPM on IL-10. The fact that anti-inﬂammatory cytokine IL-
10, with a protective effect, is decreased with the use of VPA and
TPM, and together with the observed increased level of IL-1a,
suggests a net effect of a proconvulsive type. However, the
decrease in IL-1b, IL-6 and TNF-a levels, even if not statistically
signiﬁcant, is a ﬁnding that contrasts with the decrease in IL-10.
Importantly, other cytokines such as IL-1Ra and IL-2, which were
not included in our study might also contribute to the net result.
Another limitation of our study and similar ones in the
literature is the lack of clinical correlation: whether the
therapeutic effect of AEDs is mediated by their reducing a
proconvulsant cytokine or augmenting the synthesis or release
of a protective cytokine, and whether the observed changes at 6 or
12 months are related to seizure control are important clinical
questions. We could not examine this variable in our study, in
which being seizure-free for at least one week was an inclusion
criterion by deﬁnition.
Differences between studies may be related to the differences in
study models (clinical vs. experimental), different age groups, and
the duration and dosage of AED treatment. Seizures cause changes
in cerebral tissue micro-environment, causing the glial cell release
of cytokines.11,12 But some contrasting reports suggest that
increased production of cytokines from peripheral blood mono-
nuclear cells was not evident and was not reﬂect brain cytokine
levels.34,35
The results of this study demonstrated that VPA and TPM might
lead to changes in the levels of cytokines in epileptic patients.
However, further studies including blood and CSF cytokine levels
with longer and closer follow-up are warranted to interpret the
value of these effects in the pathogenesis and treatment of
epilepsy, as well as their relation with the systemic immunity of
the patient.
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